Nobiten (Nebivolol)

Nebivolol, the active ingredient in Nobiten, is a beta blocker presented as an oral tablet for oral use. It lowers elevated blood pressure and is prescribed for adults with hypertension and certain cardiac conditions. It is indicated for the management of high blood pressure and may be used as part of combination therapy to improve cardiovascular outcomes.

GNH USA supplies Nobiten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to strict quality standards and provides reliable sourcing for regulated markets.

Nebivolol is used primarily in the cardiovascular system to control blood pressure and support heart function.

- Hypertension: reduces systolic and diastolic blood pressure, helping prevent stroke and heart attack in adults with primary hypertension. - Heart failure with reduced ejection fraction: improves left‑ventricular function and decreases hospitalization risk in patients with chronic heart failure. - Post‑myocardial infarction: assists in secondary prevention by maintaining optimal blood pressure and reducing cardiac workload. - Chronic stable angina (off‑label in some regions): may alleviate chest pain by lowering myocardial oxygen demand.

Nebivolol is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Dizziness or light‑headedness: related to blood‑pressure lowering. - Fatigue or tiredness: especially during dose titration. - Nasal congestion: occasional mild rhinitis. - Bradycardia: heart rate below 60 bpm in some patients. - Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or heart block: may require medical attention. - Symptomatic hypotension: marked drop in blood pressure causing faintness. - Bronchospasm: especially in patients with underlying asthma or COPD. - Allergic reactions: rash, itching, or angio‑edema. - Acute heart failure decompensation: rare worsening of cardiac status.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Blood pressure monitoring: ensure adequate control without excessive hypotension. - Heart rate assessment: watch for bradycardia, especially in patients on other rate‑lowering agents. - Asthma or chronic obstructive pulmonary disease: use with caution due to possible bronchospasm. - Concomitant antihypertensives: adjust doses to avoid additive hypotensive effects. - Renal or hepatic impairment: consider dose adjustment based on clinical judgment. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol may interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective beta‑blockers (e.g., propranolol): may cause excessive β‑blockade. - Calcium‑channel blockers verapamil or diltiazem: increase nebivolol plasma levels. - Clonidine abrupt withdrawal: can precipitate severe hypertension.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycemics: nebivolol may mask hypoglycemia symptoms. - Other antihypertensives (ACE inhibitors, ARBs): monitor for additive blood‑pressure reduction.